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1. INTRODUCTION {#jcla23284-sec-0005}
===============

Gastric cancer (GC) is one of the main causes of cancer‐related death worldwide.[1](#jcla23284-bib-0001){ref-type="ref"} More than 950 000 new GC patients are reported every year.[1](#jcla23284-bib-0001){ref-type="ref"} GC is separated into true gastric adenocarcinomas and gastro‐esophageal junction adenocarcinomas anatomically.[2](#jcla23284-bib-0002){ref-type="ref"} GC ranks the 3rd most comment cancer death in China.[3](#jcla23284-bib-0003){ref-type="ref"} Up to date; the pathogenesis of GC remains unclear. Previous studies indicated that *H pylori* infection, smoking, low consumption of fruits and vegetables, alcohol, and high salt intake contribute to the risk of GC[4](#jcla23284-bib-0004){ref-type="ref"}, [5](#jcla23284-bib-0005){ref-type="ref"} However, not all GC patients had these exposed factors, indicating that other aspects including genetic factors may also affect the carcinogenesis of GC.[1](#jcla23284-bib-0001){ref-type="ref"}, [6](#jcla23284-bib-0006){ref-type="ref"}

The insulin‐like growth factor (IGF) signaling pathway is a regulatory system including IGF‐1, IGF‐2, the two IGF receptors (IGF‐1R and IGF‐2R), and the six binding proteins (IGFBP1‐6). This signaling pathway was reported to stimulate cell proliferation and inhibits apoptosis.[7](#jcla23284-bib-0007){ref-type="ref"} Animal experiments suggest that IGF‐I may promote tumorigenesis.[8](#jcla23284-bib-0008){ref-type="ref"} IGF‐1 is located on 12q22--24.1. Studies have demonstrated that genetic variations in IGF‐1 gene influence the IGF‐1 levels.[9](#jcla23284-bib-0009){ref-type="ref"} Shitara et al[10](#jcla23284-bib-0010){ref-type="ref"} indicated that variants in IGF‐1 gene were associated with the GC prognosis. Several studies investigated the relationship between rs2195239 polymorphism in IGF‐1 gene and different cancer risks[11](#jcla23284-bib-0011){ref-type="ref"}, [12](#jcla23284-bib-0012){ref-type="ref"}, [13](#jcla23284-bib-0013){ref-type="ref"} including GC.[14](#jcla23284-bib-0014){ref-type="ref"} However, Ennishi et al[14](#jcla23284-bib-0014){ref-type="ref"} did not obtain significant results in this Japanese population. In addition, no Chinese study investigated the link between rs2195239 polymorphism and risk of GC in Chinese individuals previously. In order to uncover this potential association, we designed this hospital‐based case‐control study in a Chinese Han population.

2. PATIENTS AND METHODS {#jcla23284-sec-0006}
=======================

2.1. Subjects {#jcla23284-sec-0007}
-------------

In this case‐control study, 361 newly diagnosed and histologically confirmed GC patients and 418 sex‐ and age‐matched controls were recruited from the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine (Xianyang, China). The individuals with gastritis, other cancers, or gastric ulcers were excluded from this study. The control groups were individuals receiving health examinations in the hospital at the same period.

The clinical information including age, sex, smoking status, and alcohol was collected from each participant through a structured questionnaire. Smokers and drinkers were the individuals who smoked one cigarette every day for more than 1 year and those who drank at least twice every week for over half a year, respectively. Clinical information including the *H pylori* infection, TNM stage, tumor size, localization, differentiation, metastasis, and histology was obtained from the medical record. The study was approved by the Ethics Committee of the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, and it met the standards of Declaration of Helsinki. Written informed consent was obtained from each subject.

2.2. Blood sampling and genotyping {#jcla23284-sec-0008}
----------------------------------

According to manufacturer\'s instructions, genomic DNA of peripheral leukocytes was extracted using the TIANamp Blood DNA Kit (Qiagen). Rs2195239 polymorphism was genotyped by use of a custom‐by‐design 48‐Plex SNP scan TM Kit (Genesky Biotechnologies Inc.). About 10% of selected samples were validated with direct sequencing to verify the genotyping accuracy.[15](#jcla23284-bib-0015){ref-type="ref"}, [16](#jcla23284-bib-0016){ref-type="ref"} The concordance of genotypes in the repeated samples was 100%.

2.3. Statistical analysis {#jcla23284-sec-0009}
-------------------------

Using the chi‐square test, the differences in frequency distributions of dichotomous variable between cases and controls were evaluated. The Hardy‐Weinberg equilibrium (HWE) for IGF‐1 gene rs2195239 polymorphism was evaluated among the control individuals.[17](#jcla23284-bib-0017){ref-type="ref"}, [18](#jcla23284-bib-0018){ref-type="ref"}, [19](#jcla23284-bib-0019){ref-type="ref"} Logistic regression models were used to address the relationship between rs2195239 polymorphism and GC risk. Odds ratios (ORs) and their 95% confidence intervals (95% CI) were figured out without or with adjustment for age and sex. Subgroup analyses were conducted by sex, age, smoking, and alcohol. The associations between IGF‐1 rs2195239 polymorphism and clinical characteristics of GC were also explored. All analyses with *P* \< .05 value were significant. SPSS 22.0 software (SPSS Inc.) was used to deal with all statistical analyses.

3. RESULTS {#jcla23284-sec-0010}
==========

3.1. Characteristics of the study population {#jcla23284-sec-0011}
--------------------------------------------

The demographic data of all participants are shown in Table [1](#jcla23284-tbl-0001){ref-type="table"}. A total of 361 GC patients with age of 56.25 ± 5.99 years and 418 healthy controls with age of 56.42 ± 6.73 years were enrolled in this study. For cases and controls, the distribution of age and sex had no significant differences. The percentages of smoking, *H pylori* infection, and drinking were higher in the case groups compared with the control groups. Clinical information of GC patients including the tumor size, R classification, Lauren classification, metastasis, histological grade, TNM, tumor location, and histology is presented in Table [1](#jcla23284-tbl-0001){ref-type="table"}.

###### 

Patient demographics and risk factors in gastric cancer

  Characteristics             Case (N = 361)   Control (N = 418)   *P*
  --------------------------- ---------------- ------------------- --------
  Age                         58.50 ± 10.11    58.71 ± 9.73        .760
  Sex                                                              
  Male                        192 (53.2%)      225 (53.8%)         .858
  Female                      169 (46.8%)      193 (46.2%)         
  Smoking                                                          
  Yes                         250 (69.3%)      219 (52.4%)         \<.001
  No                          111 (30.7%)      199 (47.6%)         
  Alcohol                                                          
  Yes                         256 (70.9%)      210 (50.2%)         \<.001
  No                          105 (29.1%)      208 (49.8%)          
  *H pylori*                                                       
  Seronegative                115 (31.9%)      217 (51.9%)         \<.001
  Seropositive                246 (68.1%)      201 (48.1%)         
  Tumor size                                                       
  \>4 cm                      183 (50.7%)                           
  ≤4 cm                       178 (49.3%)                           
  R classification                                                 
  R0                          101 (28.0%)                           
  R1                          204 (56.5%)                           
  R2                          56 (15.5%)                            
  Lauren classification                                            
  Intestinal                  217 (60.1%)                           
  Diffuse                     139 (38.5%)                           
  Mixed                       5 (1.4%)                              
  Metastasis                                                       
  M0                          337 (93.4%)                           
  M1                          24 (6.6%)                             
  Histological grade                                               
  Well differentiated         57 (15.8%)                            
  Moderately differentiated   189 (52.4%)                           
  Poorly differentiated       115 (31.9%)                           
  TNM                                                              
  Ⅰ                           88 (24.3%)                            
  Ⅱ                           120 (33.2%)                           
  Ⅲ                           88 (24.4%)                            
  Ⅳ                           65 (18.1%)                            
  Location                                                         
  Cardia                      106 (29.4%)                           
  Non‐cardia                  255 (70.6%)                           
  Histology                                                        
  Adenocarcinoma              344 (95.3%)                           
  Not Adenocarcinoma          17 (4.7%)                             

R0: No cancer infiltration at the margin; R1: Microscopic cancer infiltration; R2: Macroscopic cancer infiltration.
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3.2. Association between IGF‐1 gene rs2195239 polymorphism and GC risk {#jcla23284-sec-0012}
----------------------------------------------------------------------

Using logistic tests, the link between IGF‐1 gene rs2195239 polymorphism and GC susceptibility was analyzed in five genetic models (Table [2](#jcla23284-tbl-0002){ref-type="table"}). The rs2195239 polymorphism met with HWE. In this study, data showed that the GG genotype or G allele was related with decreased risk for GC (GG vs CC: OR, 0.59; 95% CI, 0.36‐0.97; *P* = .036; G vs C: OR, 0.77; 95% CI, 0.62‐0.95; *P* = .015). After adjusting for sex and age, these associations were still significant.

###### 

Genotype frequencies of IGF‐1 gene polymorphisms in cases and controls

  Models         Genotype      Case (n, %)   Control (n, %)         OR (95% CI)            *P*‐value              [^a^](#jcla23284-note-0003){ref-type="fn"}OR (95% CI)   [^a^](#jcla23284-note-0003){ref-type="fn"} *P*‐value
  -------------- ------------- ------------- ---------------------- ---------------------- ---------------------- ------------------------------------------------------- ------------------------------------------------------
  rs2195239                                                                                                                                                               
  Co‐dominant    CC            183 (50.8%)   179 (42.9%)            1.00                                          1.00                                                    ---
  Heterozygote   CG            147 (40.8%)   188 (45.1%)            0.77 (0.57‐1.04)       .085                   0.76 (0.57‐1.03)                                        .077
  Homozygote     GG            30 (8.3%)     50 (12.0%)             **0.59 (0.36‐0.97)**   **.036**               **0.58 (0.35‐0.95)**                                    **.030**
  Dominant       CC            183 (50.8%)   179 (42.9%)            1.00                   ---                    1.00                                                    ---
  GG + CG        177 (49.2%)   238 (57.1%)   **0.73 (0.55‐0.97)**   **.030**               **0.72 (0.54‐0.96)**   **.026**                                                
  Recessive      CG + CC       330 (91.7%)   367 (88.0%)            1.00                   ---                    1.00                                                    ---
  GG             30 (8.3%)     50 (12.0%)    0.67 (0.41‐1.07)       .094                   0.66 (0.41‐1.06)       .083                                                    
  Allele         C             513 (71.3%)   546 (65.5%)            1.00                   ---                    ---                                                     ---
  G              207 (28.8%)   288 (34.5%)   **0.77 (0.62‐0.95)**   **.015**               ---                    ---                                                     

The genotyping was successful in 360 cases and 417 controls for rs2195239.

Bold values are regarded as statistically significant.

Adjustment with age and sex.
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Stratified analyses were conducted by sex, age, smoking, and alcohol. IGF‐1 gene rs2195239 polymorphism was related to decreased risk for GC patients among then on‐smokers, non‐drinkers, seronegative *H pylori,* and age \<60 years groups (Table [3](#jcla23284-tbl-0003){ref-type="table"}), indicating that individuals exposing to those factors were not prone to GC.

###### 

Stratified analyses between rs2195239 polymorphisms and the risk of gastric cancer

  Variable       rs2195239 (case/control)   CG vs CC   GG vs CC   GG vs CC + CG                  GG + CG vs CC                                             
  -------------- -------------------------- ---------- ---------- ------------------------------ ---------------------------- ---------------------------- ------------------------------
  Age (y)                                                                                                                                                  
  \<60           96/96                      77/106     11/28      0.73 (0.48‐1.09); .124         **0.39 (0.19‐0.83); .015**   **0.46 (0.22‐0.95); .036**   **0.66 (0.44‐0.97); .004**
  ≥60            87/83                      70/82      19/22      0.83 (0.53‐1.28); .389         0.82 (0.42‐1.63); .579       0.90 (0.47‐1.73); .752       0.82 (0.55‐1.25); .360
  Sex                                                                                                                                                      
  Male           100/104                    79/97      13/97      0.86 (0.57‐1.28); .451         0.59 (0.28‐1.22); .156       0.63 (0.31‐1.28); .204       0.80 (0.55‐1.18); .269
  Female         83/75                      68/91      17/91      0.68 (0.43‐1.05); .082         0.57 (0.29‐1.13); .105       0.69 (0.36‐1.32); .264       **0.65 (0.43‐0.99); .044**
  Smoking                                                                                                                                                  
  Yes            114/114                    113/83     22/21      1.36 (0.93‐2.00); .116         1.05 (0.55‐2.00); .889       0.91 (0.49‐1.70); .766       1.30 (0.90‐1.87); .161
  No             69/65                      34/105     6/29       **0.31 (0.18‐0.52); \<.001**   **0.26 (0.11‐0.61); .002**   0.45 (0.20‐1.03); .058       **0.30 (0.18‐0.48); \<.001**
  Alcohol                                                                                                                                                  
  Yes            118/86                     115/99     22/24      0.85 (0.58‐1.25); .399         0.67 (0.35‐1.27); .218       0.73 (0.40‐1.34); .307       0.81 (0.56‐1.18); .269
  No             65/93                      32/89      8/26       **0.52 (0.31‐0.87); .013**     0.44 (0.19‐1.03); .060       0.57 (0.25‐1.32); .190       **0.50 (0.31‐0.81); .005**
  *H pylori*                                                                                                                                               
  Seropositive   113/86                     110/93     22/22      0.91 (0.41‐1.35); .639         0.76 (0.40‐1.46); .413       0.80 (0.43‐1.49); .478       0.88 (0.61‐1.28); .510
  Seronegative   70/93                      37/95      8/28       **0.52 (0.32‐0.85); .009**     **0.38 (0.16‐0.88); .025**   0.50 (0.22‐1.14); .100       **0.49 (0.31‐0.77); .002**

Bold values are statistically significant (*P* \< .05).
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3.3. Association between IGF‐1 gene rs2195239 polymorphism and clinical features {#jcla23284-sec-0013}
--------------------------------------------------------------------------------

Next, we explored the relationship between IGF‐1 gene rs2195239 polymorphism and clinical features of GC patients (Table [4](#jcla23284-tbl-0004){ref-type="table"}). The IGF‐1 gene rs2195239 polymorphism was associated with the tumor size, TNM stage, and adenocarcinoma among GC patients.

###### 

The associations between IGF‐1 rs2195239 polymorphism and clinical characteristics of gastric cancer

  Characteristics          Genotype distributions                                                             
  ------------------------ ------------------------ ---------------------------- ---------------------------- ----------------------------
  Tumor size                                                                                                  
  \>4 cm/≤4 cm             106/77                   66/81                        11/19                        77/100
  OR (95% CI); *P*‐value   1.0 (reference)          **0.59 (0.38‐0.92); .019**   **0.42 (0.19‐0.94); .030**   **0.56 (0.37‐0.85); .006**
  Metastasis                                                                                                  
  M1/M0                    10/173                   11/136                       3/27                         14/163
  OR (95% CI); *P*‐value   1.0 (reference)          0.40 (0.58‐3.39); .455       1.92 (0.50‐7.43); .336       1.49 (0.64‐3.44); .352
  Histological grade                                                                                          
  PD/WD                    61/35                    48/17                        6/5                          54/22
  OR (95% CI); *P*‐value   1.0 (reference)          1.62 (0.81‐3.24); .170       0.69 (0.20‐2.42); .559       1.41 (0.74‐2.69); .299
  Histological grade                                                                                          
  PD/MD                    61/87                    48/82                        6/19                         54/101
  OR (95% CI); *P*‐value   1.0 (reference)          0.84 (0.52‐1.35); .464       0.45 (0.17‐1.19); .102       0.76 (0.48‐1.21); .253
  R classification                                                                                            
  R2/R1                    32/98                    17/89                        7/16                         24/105
  OR (95% CI); *P*‐value   1.0 (reference)          0.59 (0.30‐1.13); .106       1.34 (0.51‐3.55); .555       0.70 (0.39‐1.27); .240
  R classification                                                                                            
  R2/R0                    32/53                    17/41                        7/7                          24/48
  OR (95% CI); *P*‐value   1.0 (reference)          0.69 (0.35‐1.41); .302       1.66 (0.53‐5.16); .381       0.83 (0.43‐1.60); .574
  Location                                                                                                    
  Cardia/Non‐cardia        47/136                   50/97                        8/22                         58/119
  OR (95% CI); *P*‐value   1.0 (reference)          1.49 (0.93‐2.40); .099       1.05 (0.44‐2.52); .909       1.41 (0.89‐2.23); .139
  TNM                                                                                                         
  Ⅲ+Ⅳ/Ⅰ+Ⅱ                  90/93                    55/92                        8/22                         63/114
  OR (95% CI); *P*‐value   1.0 (reference)          **0.62 (0.40‐0.96); .032**   **0.38 (0.16‐0.89); .022**   **0.57 (0.37‐0.87); .009**
  Histology                                                                                                   
  Adenocarcinoma/NOT       140/7                    142/5                        25/5                         167/10
  OR (95% CI); *P*‐value   1.0 (reference)          1.42 (0.44‐4.58); .556       **0.25 (0.07‐0.85); .018**   0.84 (0.31‐2.25); .721

Bold values are statistically significant (*P* \< .05). R0: no cancer infiltration at the margin; R1: microscopic cancer infiltration; R2: macroscopic cancer infiltration.

Abbreviations: MD, moderately differentiation; PD, poorly differentiation; WD, well differentiation.
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4. DISCUSSION {#jcla23284-sec-0014}
=============

In this study, data indicated that IGF‐1 gene rs2195239 polymorphism was related to decreased risk for GC in Chinese individuals. In addition, IGF‐1 gene rs2195239 polymorphism conferred decreased risk for GC patients among the non‐smokers, non‐drinkers, seronegative *H pylori*, and age \<60 years groups. Furthermore, rs2195239 polymorphism was related to the tumor size, TNM stage, and adenocarcinoma among GC patients.

Recently, a host of studies explored the potential association between IGF‐1 gene rs2195239 polymorphism and various cancer risks. However, they obtained conflicting findings. Canzian et al[20](#jcla23284-bib-0020){ref-type="ref"} firstly investigated the relationship between rs2195239 polymorphism and breast cancer (BC) risk in a Caucasian population. They showed that rs2195239 polymorphism was not related to BC risk.[20](#jcla23284-bib-0020){ref-type="ref"} Another study from America[13](#jcla23284-bib-0013){ref-type="ref"} replicated above negative results. Although no associations were found between BC risk and IGF‐1 gene rs2195239 polymorphism in a Chinese study, they indicated that this SNP influenced on IGF‐I activity in local tissues of BC.[21](#jcla23284-bib-0021){ref-type="ref"} They also suggested that another SNP of IGF‐I gene (rs7965399) was associated with the risk of BC.[21](#jcla23284-bib-0021){ref-type="ref"} Two studies from Japan and America investigated IGF‐1 gene rs2195239 polymorphism in pancreatic cancer, but with inconsistent findings. Nakao et al[22](#jcla23284-bib-0022){ref-type="ref"} showed that this SNP was not related to pancreatic cancer susceptibility, while Dong et al[13](#jcla23284-bib-0013){ref-type="ref"} found rs2195239 polymorphism decreased the risk of pancreatic cancer. The gene functional polymorphism distribution among different races, various sample sizes, genetic heterogeneity, and clinical heterogeneity may contribute to these disaccords. No significant associations were also indicated in other cancers including prostate cancer,[23](#jcla23284-bib-0023){ref-type="ref"} testicular germ cell tumors,[24](#jcla23284-bib-0024){ref-type="ref"} and multiple myeloma.[11](#jcla23284-bib-0011){ref-type="ref"} Regarding GC, only one study from Japan[14](#jcla23284-bib-0014){ref-type="ref"} has addressed the relationship between IGF‐1 gene rs2195239 polymorphism and GC risk.[25](#jcla23284-bib-0025){ref-type="ref"} However, no association was observed in the Japanese population.[25](#jcla23284-bib-0025){ref-type="ref"} In this study, we showed that IGF‐1 gene rs2195239 polymorphism was related to decreased risk for GC in Chinese Han population, which was in accord with the findings of a recent meta‐analysis by Xu et al.[26](#jcla23284-bib-0026){ref-type="ref"} Xu et al found that rs2195239 polymorphism reduced the overall cancer risk, as well as decreasing cancer risk in Asian populations.[26](#jcla23284-bib-0026){ref-type="ref"} It is obvious that the findings of this study were different from those of the Japanese study.[25](#jcla23284-bib-0025){ref-type="ref"} Potential factor may contribute to their conflicting results. First, genetic heterogeneity for GC existed in Chinese and Japanese races. Third, clinical heterogeneity was unnegligible factors. Fourth, the sample sizes varied among this study and the Japanese study. Additionally, subgroup analysis found that IGF‐1 gene rs2195239 polymorphism was related to decreased risk for GC patients among the non‐smokers, non‐drinkers, seronegative *H pylori*, and age \<60 years groups. Furthermore, the genotypes of IGF‐1 gene rs2195239 polymorphism were related to the tumor size, tumor clinical stage, and pathological types for GC patients.

Several limitations of this study need to be addressed. First, the sample size was not large enough. Second, the functional significance of other SNPs was unknown and the study does not include any other SNPs. Third, information about expose factors was not enough. Fourth, whether the interaction between *H pylori* infection and IGF‐1 gene rs2195239 polymorphism accounted for decreased risk of GC should be studied. Last, this study is lack of a replication sample set to confirm the positive findings.

In conclusion, IGF‐1 gene rs2195239 polymorphism is associated with decreased risk for GC in this Chinese population. Further studies in other populations with larger sample sizes are warranted.
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